Evidence map›Paper›PMID 40526827›Full record

ReviewACS applied materials & interfaces2025

The Nanocarrier Landscape─Evaluating Key Drug Delivery Vehicles and Their Capabilities: A Translational Perspective.

Fahd Khalid-Salako, Soodeh Salimi Khaligh, Farzaneh Fathi, Osman C Demirci, Nazlı Öncer, Hasan Kurt, Meral Yüce

Abstract readReview
In one paragraph

Review in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. EnterohemorrhagicACS omega · 2026
    Article
  9. Iron-Based Nanoparticles as Delivery Tools.Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Quo Vadis translational neuroscience?Translational neuroscience · 2026
    Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fahd Khalid-SalakoSUNUM Nanotechnology Research and Application Centre, Sabanci University, Istanbul 34956, Türkiye.ORCID 0000-0003-4795-2423
Soodeh Salimi KhalighSUNUM Nanotechnology Research and Application Centre, Sabanci University, Istanbul 34956, Türkiye.
Farzaneh FathiPharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil 56131-56491, Iran.
Osman C DemirciGebze Technical University, Department of Environmental Engineering, Gebze, Kocaeli 41400, Türkiye.
Nazlı ÖncerSUNUM Nanotechnology Research and Application Centre, Sabanci University, Istanbul 34956, Türkiye.
Hasan KurtDepartment of Bioengineering, Royal School of Mines, Imperial College London, London SW7 2AZ, U.K.ORCID 0000-0002-1677-644X
Meral YüceSUNUM Nanotechnology Research and Application Centre, Sabanci University, Istanbul 34956, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The field of nanomedicine is currently in a revolutionary phase, propelled by the significant potential of nanoparticles, which offer several advantages over traditional drug delivery systems. The purpose of this paper is to aggregate contemporary knowledge of nanoparticles developed and applied in drug delivery across major disease classes. Accordingly, we offer, through a thorough search of the literature, a comprehensive overview of the prevalent nanoparticles used in drug delivery systems, covering polymeric, lipid-based, inorganic, and carbon-based nanoparticles, and discuss their advantages and limitations. This work primarily focuses on studies published in the last 5 years, aiming to provide an up-to-date assessment of the critical nanoparticles in drug delivery. Narratively, we synthesize a comprehensive overview of the state-of-the-art in nanocarrier technology, providing in-depth insights into the key nanoparticle types presented in the contemporary literature, their fundamental benefits, potential clinical applications, and limitations impeding their development and adoption. We note that there are gaps and opportunities for concerted efforts focused on developing biocompatible and biodegradable nanoparticles, establishing scalable and cost-effective manufacturing processes, and addressing regulatory challenges associated with nanoparticle-based drug delivery systems. These challenges persist despite the immense translational success of nanoparticle-based drug delivery systems and necessitate continued interdisciplinary research and cross-industry collaboration among scientists, clinicians, and regulatory bodies.

Indexed as

Drug CarriersDrug Delivery SystemsNanoparticlesAnimalsHumansNanomedicineTranslational Research, BiomedicalDrug Carriersbiocompatibilitynanocarriersnanoparticle drug deliverypersonalized nanomedicinetheranosticstoxicity

Identifiers

PMID40526827
PMCPMC12232268

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.